A detailed history of Versant Capital Management, Inc transactions in Incyte Corp stock. As of the latest transaction made, Versant Capital Management, Inc holds 76 shares of INCY stock, worth $5,907. This represents 0.0% of its overall portfolio holdings.

Number of Shares
76
Previous 76 -0.0%
Holding current value
$5,907
Previous $4,000 25.0%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 05, 2024

BUY
$51.18 - $63.75 $3,275 - $4,080
64 Added 533.33%
76 $4,000
Q4 2023

Jan 08, 2024

BUY
$52.16 - $64.19 $521 - $641
10 Added 500.0%
12 $0
Q3 2023

Oct 11, 2023

SELL
$57.77 - $65.93 $693 - $791
-12 Reduced 85.71%
2 $0
Q2 2023

Jul 10, 2023

BUY
$60.95 - $75.51 $731 - $906
12 Added 600.0%
14 $0
Q3 2022

Dec 30, 2022

SELL
$66.18 - $82.86 $264 - $331
-4 Reduced 66.67%
2 $0
Q1 2022

Apr 29, 2022

BUY
$66.02 - $79.71 $264 - $318
4 Added 200.0%
6 $0
Q3 2021

Oct 29, 2021

SELL
$68.67 - $84.02 $755 - $924
-11 Reduced 84.62%
2 $0
Q1 2021

Apr 27, 2021

BUY
$76.02 - $100.5 $836 - $1,105
11 Added 550.0%
13 $1,000
Q3 2020

Nov 02, 2020

SELL
$85.07 - $109.69 $425 - $548
-5 Reduced 71.43%
2 $0
Q2 2020

Jul 16, 2020

BUY
$74.18 - $108.93 $370 - $544
5 Added 250.0%
7 $0
Q1 2020

Apr 17, 2020

SELL
$63.18 - $85.97 $568 - $773
-9 Reduced 81.82%
2 $0
Q3 2019

Oct 18, 2019

BUY
$72.82 - $86.52 $655 - $778
9 Added 450.0%
11 $0
Q1 2019

Apr 23, 2019

BUY
$63.56 - $88.17 $127 - $176
2 New
2 $0
Q1 2019

Apr 23, 2019

SELL
$63.56 - $88.17 $254 - $352
-4 Closed
0 $0
Q4 2015

Apr 23, 2018

BUY
N/A
4
4 $0

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $17.3B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Versant Capital Management, Inc Portfolio

Follow Versant Capital Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Versant Capital Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Versant Capital Management, Inc with notifications on news.